Literature DB >> 25340499

Possible contribution of aminopeptidase N (APN/CD13) to migration and invasion of human osteosarcoma cell lines.

Wenqing Liang1, Bo Gao2, Guojian Xu1, Dong Weng1, Minghua Xie1, Yu Qian1.   

Abstract

Osteosarcoma is the most common primary malignancy of the bone. Aminopeptidase N (APN/CD13), a Zn+2-dependent ectopeptidase localized on the cell surface, is widely considered to influence the invasion mechanism. This study explores the potential involvement of APN in migration and invasion of human osteosarcoma cells in vitro using inhi-bitors and activators of APN. Cells treated with APN inhibitor bestatin displayed decreased migration and invasion in a Boyden chamber Transwell assay. Western blotting revealed reduced levels of mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathway proteins, reduced phosphorylation of p38, ERK1/2 and JNK and decreased levels of NF-κB. Bestatin treatment also lowered APN, matrix metalloproteinase (MMP)-2 and -9 enzymatic activity and their mRNA expression. Reduced MMP-2 and -9 protein levels were also observed. By comparison, cells treated with cytokine interleukin-6 (IL-6), a stimulator of APN, displayed increased migration and invasion. Western blotting revealed increased levels of MAPK and PI3K pathway proteins, phosphorylated p38, ERK1/2 and JNK, and NF-κB. IL-6 treatment also increased APN and MMP-2 and -9 enzymatic activity. An increase of APN, MMP-2 and -9 mRNA levels, and MMP-2 and -9 protein levels was also observed. Together these experiments reveal potential enzymatic and signalling roles for APN in osteosarcoma and establish a starting point for an in-depth analysis of the role of APN in regulating invasiveness. A deeper knowledge about the regulatory mechanisms of APN may contribute to the development of anti-metastatic therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25340499     DOI: 10.3892/ijo.2014.2664

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Single nucleotide polymorphisms of HER2 related to osteosarcoma susceptibility.

Authors:  Da-Jiang Xin; Guo-Dong Shen; Jian Song
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  CD13 inhibition augments DR4-induced tumor cell death in a p-ERK1/2-independent manner.

Authors:  Jun Ni; Xiaofei Wang; Yue Shang; Yi Li; Shuzhen Chen
Journal:  Cancer Biol Med       Date:  2021-03-12       Impact factor: 4.248

3.  Ubenimex, an APN inhibitor, could serve as an anti‑tumor drug in RT112 and 5637 cells by operating in an Akt‑associated manner.

Authors:  Xiaoqing Wang; Yang Liu; Wei Liu; Yongfei Zhang; Feng Guo; Lijuan Zhang; Mingyu Cui; Shuai Liu; Rongde Wu
Journal:  Mol Med Rep       Date:  2018-01-09       Impact factor: 2.952

4.  Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide.

Authors:  Konstantin Byrgazov; Claes Anderson; Benjamin Salzer; Eva Bozsaky; Rolf Larsson; Joachim Gullbo; Manfred Lehner; Fredrik Lehmann; Ana Slipicevic; Leo Kager; Mårten Fryknäs; Sabine Taschner-Mandl
Journal:  Ther Adv Med Oncol       Date:  2020-07-29       Impact factor: 5.485

5.  Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.

Authors:  Torsten Kessler; Ariane Baumeier; Caroline Brand; Michael Grau; Linus Angenendt; Saliha Harrach; Ursula Stalmann; Lars Henning Schmidt; Georg Gosheger; Jendrik Hardes; Dimosthenis Andreou; Johannes Dreischalück; Georg Lenz; Eva Wardelmann; Rolf M Mesters; Christian Schwöppe; Wolfgang E Berdel; Wolfgang Hartmann; Christoph Schliemann
Journal:  Transl Oncol       Date:  2018-08-17       Impact factor: 4.243

Review 6.  Nanocomposites as biomolecules delivery agents in nanomedicine.

Authors:  Magdalena Bamburowicz-Klimkowska; Magdalena Poplawska; Ireneusz P Grudzinski
Journal:  J Nanobiotechnology       Date:  2019-04-03       Impact factor: 9.429

7.  Ubenimex induces apoptotic and autophagic cell death in rat GH3 and MMQ cells through the ROS/ERK pathway.

Authors:  Yanjun Wang; Bo Pang; Rui Zhang; Yibing Fu; Qi Pang
Journal:  Drug Des Devel Ther       Date:  2019-09-12       Impact factor: 4.162

Review 8.  Leukocyte Membrane Enzymes Play the Cell Adhesion Game.

Authors:  Georgina I López-Cortés; Laura Díaz-Alvarez; Enrique Ortega
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

Review 9.  Coronavirus Receptors as Immune Modulators.

Authors:  Charan Kumar V Devarakonda; Emily Meredith; Mallika Ghosh; Linda H Shapiro
Journal:  J Immunol       Date:  2020-12-30       Impact factor: 5.422

10.  A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.

Authors:  Masafumi Yamashita; Hiroshi Wada; Hidetoshi Eguchi; Hisataka Ogawa; Daisaku Yamada; Takehiro Noda; Tadafumi Asaoka; Koichi Kawamoto; Kunihito Gotoh; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Int J Oncol       Date:  2016-04-25       Impact factor: 5.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.